Seres Therapeutics, Inc. (MCRB)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 66
- Market Cap
- $46M
About Seres Therapeutics, Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
SentiSense also tracks daily options readings for Seres Therapeutics, Inc.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Seres Therapeutics, Inc. stock analysis, sentiment tracking, and market intelligence on SentiSense.